

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on July 5, 2007.

Frank C Eisenschenk  
Frank C. Eisenschenk, Ph.D., Patent Attorney

INFORMATION DISCLOSURE STATEMENT  
Examining Group 3747  
Patent Application  
Docket No. INN-136  
Serial No. 10/588,420

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 3747  
Applicants : Francois Romagne, Jerome Tiollier  
Serial No. : 10/588,420  
Filed : August 4, 2006  
Conf. No. : 5861  
For : Composition and Method for the Treatment of Carcinoma

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 U.S.C. § 371. Applicants have been notified that a copy of the International Search Report has been made available in the national stage file as indicated on the Notice of Acceptance of the Application Under 35 U.S.C. § 371 (Form PCT/DO/EO/903). The Notice does not indicate whether copies of the references cited in the International Search Report were received by the Patent Office. Therefore, copies of the references cited in the International Search Report are enclosed for the Examiner's convenience. However, Applicants have not submitted copies of the U.S. patents cited on attached Form PTO/SB/08 pursuant to 37 C.F.R. § 1.98(a)(2)(ii). In accordance with 37 C.F.R. § 1.56, Applicants hereby request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

Published International Applications WO 95/20673 (cited as F2), WO 00/12519 (cited as F3), and WO 00/12516 (cited as F4) on the attached form PTO/SB/08 are written in a foreign language. In accordance with MPEP §609A(3), Applicants are submitting herewith a copy of the International Search Report from corresponding International Application No. PCT/IB2005/000509 which was filed on February 8, 2004. Applicants have also included U.S. Patent Nos. 7,101,711 and 6,660,723 which are believed to be English language equivalents of WO 00/12519 and WO 00/12516, respectively. Applicants further note that although the specifications of the Published International Applications are written in a foreign language, English language Abstracts are provided therewith. Applicants respectfully request that these references be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschken, Ph.D.  
Patent Attorney  
Registration No. 45,332  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/jps/sl

Attachments: Form PTO/SB/08; copies of references cited therein.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/588,420
				Filing Date	August 4, 2006
				First Named Inventor	Francois Romagne
				Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	INN-136

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-6,660,723	12-09-2003	Belmant <i>et al.</i>	All
	U2	US-7,101,711	09-05-2006	Belmant <i>et al.</i>	All
	U3	US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			
F1		WO 01/56387 A1	08-09-2001	O'DONNELL, M.	All
F2		WO 95/20673 A1	08-03-1995	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE	All
F3		WO 00/12519 A1	03-09-2000	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE	All
F4		WO 00/12516 A1	03-09-2000	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE	All
F5		WO 2004/050096 A2	06-17-2004	INNATE PHARMA	All
F6		EP 1 426 052 A1	06-09-2004	INNATE PHARMA	All
F7					

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
Sheet	2	of	2	Application Number	10/588,420
				Filing Date	August 4, 2006
				First Named Inventor	Francois Romagne
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	INN-136

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	R1	SAINT, F. et al. "Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer", <i>Urology</i> , May 2001, pp. 883-888, Vol. 57, No. 5.		
	R2	KUNZMANN, V. et al. "Stimulation of $\gamma\delta T$ cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma", <i>Blood</i> , July 15, 2000, pp. 384-392, Vol. 96, No. 2.		
	R3	WILHELM, M. et al. " $\gamma\delta T$ Cells for Immune Therapy of Patients with Lymphoid Malignancies", <i>Blood</i> , July 1, 2003, pp. 200-206, Vol. 102, No. 1.		
	R4	PONTICIELLO, A. et al. "Analysis of Local T Lymphocyte Subsets Upon Stimulation with Intravesical BCG: A Model to Study Tuberculosis Immunity", June 2004, pp. 509-514, Vol. 98, No. 6.		
	R5			
	R6			
	R7			
	R8			
	R9			
	R10			
	R11			
	R12			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.